ABIVAX (EPA:ABVX) | Finanzwire

BRIEF

published on 10/13/2025 at 14:50, 3 months 17 days ago

JP Morgan exceeds the 5% threshold at ABIVAX

Voting Rights Actions Abivax Threshold Crossing JP Morgan
BRIEF

published on 10/06/2025 at 10:05, 3 months 24 days ago

Abivax Unveils Promising New Results from Obefazimod

Abivax Obefazimod Ulcerative Colitis Clinical Trial Results
PRESS RELEASE

published on 10/06/2025 at 10:00, 3 months 24 days ago

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
Abivax announces late-breaking presentation at UEG Meeting on ABTECT Induction Trial results in patients with and without prior inadequate response to advanced therapies. Obefazimod shows clinically meaningful improvements and favorable safety profile

Abivax Obefazimod Ulcerative Colitis Clinical Trial Late-breaking Presentation
BRIEF

published on 10/05/2025 at 17:05, 3 months 25 days ago

Abivax Presents Promising 8-Week ABTECT Trial Results

Abivax Obefazimod Ulcerative Colitis Clinical Trials Safety Data
PRESS RELEASE

published on 10/05/2025 at 17:00, 3 months 25 days ago

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
Abivax announces positive results from Phase 3 ABTECT 8-Week Induction Trials on obefazimod for ulcerative colitis treatment with no new safety concerns identified, to present further abstract on October 6

Abivax Obefazimod Ulcerative Colitis Phase 3 Trial Safety Data
BRIEF

published on 10/03/2025 at 11:59, 3 months 27 days ago

JP Morgan Chase & Co. crosses the 5% threshold at ABIVAX

Voting Rights Actions Abivax Threshold Crossing JP Morgan
BRIEF

published on 09/29/2025 at 22:10, 4 months ago

Abivax Presents New Findings on Obefazimod at UEG 2025

Abivax Obefazimod Ulcerative Colitis Phase 3 Trials UEG Meeting
PRESS RELEASE

published on 09/29/2025 at 22:05, 4 months ago

Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
Abivax announces acceptance of additional late-breaking abstract from the ABTECT Phase 3 induction trials to be presented at 2025 United European Gastroenterology (UEG) Meeting

Abivax Ulcerative Colitis Gastroenterology Late-breaking Abstract ABTECT Phase 3
BRIEF

published on 09/23/2025 at 22:10, 4 months 6 days ago

Abivax: Presentation of promising data on obefazimod at the 2025 UEG congress

Abivax Obefazimod Ulcerative Colitis Phase 3 UEG Congress
PRESS RELEASE

published on 09/23/2025 at 22:05, 4 months 6 days ago

Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
Abivax announces presentation of late-breaking abstract for Obefazimod at 2025 United European Gastroenterology Meeting, showcasing potential as a new therapy for ulcerative colitis

Abivax Obefazimod Ulcerative Colitis Late-breaking Abstract UEG Meeting

Published on 01/30/2026 at 14:00, 5 hours 34 minutes ago

CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Published on 01/30/2026 at 08:35, 10 hours 59 minutes ago

Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 11 hours 34 minutes ago

Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 17 hours 19 minutes ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 19 hours 34 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

View all ACCESSWIRE

Published on 01/30/2026 at 19:13, 21 minutes ago

Total Voting Rights
Published on 01/30/2026 at 18:31, 1 hour 3 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 01/30/2026 at 18:30, 1 hour 3 minutes ago

HOL-Holdings in Company
Published on 01/30/2026 at 18:23, 1 hour 11 minutes ago

TVR-Total Voting Rights
Published on 01/30/2026 at 18:17, 1 hour 16 minutes ago

POS-Transaction in Own Shares

View all EQS

Published on 01/30/2026 at 17:45, 1 hour 49 minutes ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 08:00, 11 hours 34 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 1 day 1 hour ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 1 day 1 hour ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 1 day 1 hour ago

Cegedim generated LFL revenue growth of 1.1% in 2025

View all LES ECHOS COMFI WIRE

News